1. Scrip
  2. >>Market Snapshot

Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years

 
• By Mandy Jackson

Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.

pain killer stop headache migraine, no more suffering painkiller paracetamol aspirine merphine medicine treatment prevention and therapy
Acute treatments are used to stop migraines when they occur • Source: Shutterstock

Migraine impacts a billion people globally, including about 39 million patients in the US alone, representing a very large market that still has a lot of unmet needs despite the availability of well-known generic drugs for both prevention and acute treatment. And while three new preventive therapies launched in the US in 2018, three new acute migraine treatments may reach the market in early 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Snapshot

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

 
• By Alaric DeArment

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow

 
• By Jessica Merrill

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 
• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

More from Scrip

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

 
• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Taxes, Not Tariffs, Influence US Manufacturing, J&J CEO Says

 
• By Jessica Merrill

The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.